MediciNova obtains patent for MN-166 (ibudilast) to prevent eye cancer metastasis, expires July 2042.

MediciNova receives a Notice of Allowance for a new patent covering MN-166 (ibudilast) for preventing eye cancer metastasis. The patent is expected to expire in July 2042 and covers the use of MN-166 for preventing, ameliorating, or minimizing metastasis of eye cancer. MediciNova is a biopharmaceutical company listed on the NASDAQ Global Market and the Tokyo Stock Exchange.

May 20, 2024
3 Articles